Following three clinical trials, the FDA has approved a new preventive treatment for neonates, infants, and toddlers that prevents respiratory syncytial virus (RSV) in those age populations.
The authors expanded upon research conducted in 2015 by including deaths across different global demographics that did not occur in hospitals. This is the first study to examine the RSV disease burden in...
